PetCaseFinder

Peer-reviewed veterinary case report

Immune-related anemia in cats with feline infectious peritonitis

By Černá, Petra et al.·Published in Pathogens (Basel, Switzerland)·2025·Department of Clinical Sciences, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Immune-Mediated Hemolytic Anemia in Cats with Feline Infectious Peritonitis.

Species:
cat

Plain-English summary

A group of 45 cats with feline infectious peritonitis (FIP) were found to also have immune-mediated hemolytic anemia (IMHA), a condition where the immune system destroys red blood cells. Most of these cats had severe anemia and were treated with antiviral medications and glucocorticoids (steroids) to help manage both conditions. After treatment, 73% of the cats survived, with many showing improvement in both FIP and IMHA. However, some cats experienced relapses of either condition. This highlights the need for pet owners to be aware of anemia as a potential complication in cats with FIP.

People also search for: cat anemia treatment · feline infectious peritonitis symptoms · immune-mediated hemolytic anemia in cats · FIP treatment for cats · cat blood disorder causes

Abstract

Feline infectious peritonitis (FIP) is caused by mutated feline coronaviruses. Immune-mediated hemolytic anemia (IMHA) arises due to immune-mediated erythrocyte destruction and can be non-associative or associative with diseases such as FIP. Records of cats with FIP were reviewed to find those with associative IMHA based on exclusion of other causes of anemia and a positive saline agglutination test and/or Coombs test. The inclusion criteria were met for 45 cats (26 (58%) cats with effusive and 19 (42%) with non-effusive FIP). Median hematocrit was 18% (interquartile range [IQR] 13-20). Anemia was non-regenerative in 36 (80%) cats and regenerative in 5 (11%) cats; 4 (9%) cats had no reticulocyte count available. Concurrent thrombocytopenia was present in 18 (40%) cats. All 45 cats were treated with nucleoside analogs, and 44 (98%) cats with glucocorticoids; in 5 (11%) cats, glucocorticoids were added after starting antiviral treatment due to persistent anemia. Median follow-up was 72 days (IQR 14-246); at the time of last follow-up 33 (73%) cats had survived while 12 (27%) had died or were euthanized. Of the 33 surviving cats, 17 achieved remission of both FIP and IMHA. In three cats, FIP remission was achieved, but IMHA relapsed; in one of these, IMHA relapsed twice. FIP relapsed without IMHA in two cats, and both FIP and IMHA relapsed in one cat. In 9 cats the antiviral and glucocorticoid treatment is still ongoing at the time of the publication. Although FIP is likely an uncommon cause of associative IMHA, as more cats with FIP are treated with antiviral therapy, it is important to consider IMHA as a possible cause of anemia in cats with FIP.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40732707/